Kite Pharma
Flexible on-site
The team generally works at the office, but is provided with flexible work options (e.g. option to work remotely part-time).
👥1,001-5,000
📍Santa Monica, California
Kite Pharma

About Kite Pharma

Kite, a Gilead Company, is dedicated to achieving one of the most ambitious goals of 21st century medicine: curing cancer. This mission is at the heart of everything we do, from early research to product development. For the past three decades, members of our team have been at the forefront of cancer immunotherapy. Today, we are a leader in engineered T cell therapy, changing the paradigm of cancer treatment with what is potentially the biggest breakthrough since the introduction of combination chemotherapy more than 60 years ago. With an unrelenting drive and a singular focus on cell therapy, our team is executing on our strategy to bring life-saving therapies to patients. In all areas of the company, we are looking for the very best people who share our deep passion to cure cancer. We realize that our ambitious goals can only be achieved if every employee is fully committed to our mission and embraces our entrepreneurial spirit. If this describes you, please contact us.

Kite Pharma benefits and support

🏥Health insurance
🌴Retirement pension
🌞Healthy living stipend
🛋Home office stipend
📕Learning stipend
🍼Maternity/paternity leave
🗺Company retreat
🏖Generous vacation policy

Kite Pharma news and updates

Kite Pharma, Inc. partners with Humanigen, Inc.

Gilead Sciences ( GILD -1.7% ) unit Kite Pharma will collaborate with Humanigen ( OTCQB:HGEN +8.7% ) on a Phase 1/2 clinical trial evaluating the combination of CAR T therapy Yescarta (axicabtagene ciloleucel) and lenzilumab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

Jan 1, 2019 | seekingalpha.com

Kite Pharma, Inc. recognized as Impact Case of the Year

Finally, another of Fish’s cases, Juno Therapeutics v. Kite Pharma, was also named an “Impact Case of the Year,” an honor the firm shared with co-counsel Orrick Herrington & Sutcliffe.

Sep 8, 2022 | fr.com

Kite Pharma, Inc. invests into assets : 20 acres

“Kite Pharma purchased 20 acres for a state-of-the-art manufacturing facility.

Sep 13, 2022 | naiopmd.org

Gilead Sciences, Inc. acquired Kite Pharma, Inc. on Jan 1st 17'.

Kite was acquired by Gilead Sciences, Inc. later in 2017 after the Daiichi Sankyo partnership agreement.

Dec 7, 2022 | pharmajournalist.com

Kite Pharma, Inc. partners with Arcellx, Inc.

Gilead company Kite has entered an international strategic partnership with Arcellx for the joint development and commercialisation of the latter’s T-cell therapy, CART-ddBCMA, to treat relapsed or refractory multiple myeloma patients.

Dec 12, 2022 | pharmaceutical-technology.com

Kite Pharma, Inc. partnered with Tmunity Therapeutics, Inc. on Jun 1st 22'.

Gilead Sciences subsidiary Kite Pharma has entered into a purchase deal with Tmunity Therapeutics — the company founded by CAR-T cell pioneer Carl June — gaining access to Tmunity’s “armored” CAR-T cell platform.

Dec 21, 2022 | fdanews.com

Kite Pharma, Inc. acquired Tmunity Therapeutics, Inc. on Dec 20th 22'.

Kite’s acquisition of Tmunity, founded by Carl June, creates a strong bridge between the BioHealth Capital Region, where Kite maintains its manufacturing capabilities in Frederick, and the Greater Philadelphia biohub.

Dec 19, 2022 | biobuzz.io
See More